A Randomised, Double Blind, Placebo-Controlled Trial of the Efficacy of Hydroxychloroquine for the Community-Based Treatment of Adults With Diagnosed COVID-19

Medical Research Institute of New Zealand0 个研究点目标入组 70 人开始时间: 2020年4月8日最近更新: 2020年11月2日

适应症

试验速览

暂无简介。

•Aged 18 to 75 years.
•Laboratory confirmed SARS-CoV2 infection.
•Advised to self-manage COVID-19 in the community by the regional public health team.
•In the Investigator’s opinion, is able and willing to comply with all trial requirements.
•Baseline Flu PRO score >1.3
•Able to receive and commence randomised treatment via courier the day after consent was obtained.

•Known pregnancy or planning to become pregnant during the study period
•Currently breastfeeding
•Known maculopathy or retinal disorder.
•Known cardiac disease/dysrhythmia or prolonged QTc
•Know renal disease
•Known hepatic disease
•Known hypomagnesaemia or hypokalaemia.
•Currently using hydroxychloroquine or any 4-aminoquinoline.
•Use of medications prolonging QTc including: Class IA (quinidine, procainamide, disopyramide) and III (amiodarone, sotalol, ibutilide, dofetilide) antiarrythmics, macrolides, methadone, fluoroquinolones, domperidone, fluconazole, ondansetron, tacrolimus, tramadol, anti-retrovirals.
•Current use of tamoxifen, digoxin, tricyclics, SSRIs, antipsychotics, halfantrine, cyclosporin and anti-epileptic medications
•Current use of oral hypoglycaemics including glipizide, glyburide, gliclazide, glimepiride, repaglinide, nateglinide, metformin, rosiglitazone, pioglitazone, acarbose, miglitol, voglibose, sitagliptin, saxagliptin, vildagliptin, linagliptin, alogliptin, dapagliflozin, canagliflozin, bromocriptine.
•Sensitivity or allergy to 4-aminoquinilone compounds or any excipients used in the study
•Unable to access digital consent forms or maintain remote contact with the study team
•Have any other condition which, at the investigator’s discretion, is believed may present a safety risk or impact the feasibility of the study or the study results.

发起方